(Q42612118)

3 November 2017

title

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma (English)

1 reference

cost-effectiveness analysis

3 November 2017

0 references

1 reference

Brown R

1

1 reference

3 November 2017

Turk F

series ordinal

2

1 reference

3 November 2017

Dale P

series ordinal

3

1 reference

3 November 2017

Bousquet J

series ordinal

4

1 reference

3 November 2017

language of work or name

1 reference

1 February 2007

1 reference

3 November 2017

1 reference

3 November 2017

volume

62

1 reference

3 November 2017

issue

2

1 reference

3 November 2017

page(s)

149-153

1 reference

Urgent care costs of uncontrolled asthma in Canada, 2004.

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01310.X

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01310.X

Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01310.X

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01310.X

10.1111/J.1398-9995.2006.01310.X

21 January 2018

Identifiers

DOI

1 reference

3 November 2017

1 reference